The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Nanocarrier-based drug combination therapy for glioblastoma
Open accessAbstract
The current achievements in treating glioblastoma (GBM) patients are not sufficient because many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem cells, drug efflux pumps and DNA damage repair mechanisms. Drug combination therapies have shown increasing benefits against those challenges. With the help of nanocarriers, enhancement of the efficacy and safety could be gained using synergistic combinations of different therapeutic agents. In this review, we will discuss the major issues for GBM treatment, the rationales of drug combinations with or without nanocarriers and the principle of enhanced permeability and retention effect involved in nanomedicine-based tumor targeting and promising nanodiagnostics or -therapeutics. We will also summarize the recent progress and discuss the clinical perspectives of nanocarrier-based combination therapies. The goal of this article was to provide better understanding and key considerations to develop new nanomedicine combinations and nanotheranostics options to fight against GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa, H., Budach, V., & Jordan, A. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0389-0 · Cited by 1,429
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Glioblastoma: Overview of Disease and Treatment
Davis, M. (2016) · Clinical Journal of Oncology Nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,205
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Brown, T. J., Brennan, M. C., Li, M., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E. B., Suki, D., Sawaya, R., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1373 · Cited by 1,081
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Red‐Emissive Carbon Dots for Fluorescent, Photoacoustic, and Thermal Theranostics in Living Mice
Ge, J., Jia, Q., Liu, W., Guo, L., Liu, Q., Lan, M., Zhang, H., Meng, X., & Wang, P. (2015) · Advanced Materials · doi:10.1002/adma.201500323 · Cited by 885
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2012) · Glia · doi:10.1002/glia.21264 · Cited by 712
Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 680
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Multidimensional communication in the microenvirons of glioblastoma
Broekman, M. L., Maas, S. L. N., Abels, E. R., Mempel, T. R., Krichevsky, A. M., & Breakefield, X. O. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0025-8 · Cited by 579
Self-citationRadiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
KOMOTAR, R. J., WILSON, D. A., & CONNOLLY, E. S. (2005) · Neurosurgery · doi:10.1093/neurosurgery/57.1.n7a · Cited by 570
Rong, Y., Durden, D. L., Van Meir, E. G., & Brat, D. J. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-200606000-00001 · Cited by 567
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Overcoming therapeutic resistance in glioblastoma: the way forward
Osuka, S., & Van Meir, E. G. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89587 · Cited by 511
Hydrogels for Therapeutic Delivery: Current Developments and Future Directions
Buwalda, S. J., Vermonden, T., & Hennink, W. E. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01604 · Cited by 497
Magnetic Nanoparticles in Cancer Theranostics
Gobbo, O. L., Sjaastad, K., Radomski, M. W., Volkov, Y., & Prina-Mello, A. (2015) · Theranostics · doi:10.7150/thno.11544 · Cited by 462
Miura, Y., Takenaka, T., Toh, K., Wu, S., Nishihara, H., Kano, M. R., Ino, Y., Nomoto, T., Matsumoto, Y., Koyama, H., et al. (2013) · ACS Nano · doi:10.1021/nn402662d · Cited by 454
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
Steiniger, S. C. J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K. D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20048 · Cited by 434
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Strategy for effective brain drug delivery
Alam, M. I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Ahuja, A., & Akbar, M. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.05.003 · Cited by 415
Current approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350
Miller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Kohler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 347
Batchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy-Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 340
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z. (., & Shin, D. M. (2009) · Nanoscience and Technology · doi:10.1142/9789814287005_0025 · Cited by 321
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Current trends in the surgical management and treatment of adult glioblastoma.
Young, R. M., Jamshidi, A. M., Davis, G., & Sherman, J. H. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.05.10 · Cited by 308
Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Mathios, D., Kim, J. E., Mangraviti, A., Phallen, J., Park, C.-K., Jackson, C. M., Garzon-Muvdi, T., Kim, E., Theodros, D., Polanczyk, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2942 · Cited by 296
Sorensen, A. G., Emblem, K. E., Polaskova, P., Jennings, D., Kim, H., Ancukiewicz, M., Wang, M., Wen, P. Y., Ivy, P., Batchelor, T. T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2464 · Cited by 295
Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone
Lemée, J.-M., Clavreul, A., & Menei, P. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov119 · Cited by 295
In vivo models of primary brain tumors: pitfalls and perspectives
Huszthy, P. C., Daphu, I., Niclou, S. P., Stieber, D., Nigro, J. M., Sakariassen, P. O., Miletic, H., Thorsen, F., & Bjerkvig, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos135 · Cited by 282
The disturbed blood–brain barrier in human glioblastoma
Wolburg, H., Noell, S., Fallier-Becker, P., Mack, A. F., & Wolburg-Buchholz, K. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.02.003 · Cited by 277
Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue
D’Alessio, A., Proietti, G., Sica, G., & Scicchitano, B. M. (2019) · Cancers · doi:10.3390/cancers11040469 · Cited by 275
Sørensen, M. D., Dahlrot, R. H., Boldt, H. B., Hansen, S., & Kristensen, B. W. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12428 · Cited by 273
Cheng, Y., Dai, Q., Morshed, R. A., Fan, X., Wegscheid, M. L., Wainwright, D. A., Han, Y., Zhang, L., Auffinger, B., Tobias, A. L., et al. (2014) · Small · doi:10.1002/smll.201400654 · Cited by 271
Drug Resistance in Glioblastoma: A Mini Review
Haar, C. P., Hebbar, P., Wallace, G. C., Das, A., Vandergrift, W. A., Smith, J. A., Giglio, P., Patel, S. J., Ray, S. K., & Banik, N. L. (2012) · Neurochemical Research · doi:10.1007/s11064-011-0701-1 · Cited by 254
Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art
Karim, R., Palazzo, C., Evrard, B., & Piel, G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.026 · Cited by 252
Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma
Bastiancich, C., Danhier, P., Préat, V., & Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.034 · Cited by 252
Self-citationZhao, P., Wang, Y., Kang, X., Wu, A., Yin, W., Tang, Y., Wang, J., Zhang, M., Duan, Y., & Huang, Y. (2018) · Chemical Science · doi:10.1039/c7sc04853j · Cited by 248
SUBCUTANEOUS RESERVOIR AND PUMP FOR STERILE ACCESS TO VENTRICULAR CEREBROSPINAL FLUID
Ommaya, A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)90681-0 · Cited by 233
Safa, A. R., Saadatzadeh, M. R., Cohen-Gadol, A. A., Pollok, K. E., & Bijangi-Vishehsaraei, K. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.02.001 · Cited by 230
Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment
Ganipineni, L. P., Danhier, F., & Préat, V. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.008 · Cited by 217
Self-citationBrandenburg, S., Müller, A., Turkowski, K., Radev, Y. T., Rot, S., Schmidt, C., Bungert, A. D., Acker, G., Schorr, A., Hippe, A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1529-6 · Cited by 215
Friday, B. B., Anderson, S. K., Buckner, J., Yu, C., Giannini, C., Geoffroy, F., Schwerkoske, J., Mazurczak, M., Gross, H., Pajon, E., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor198 · Cited by 213
The role of bevacizumab in the treatment of glioblastoma
Diaz, R. J., Ali, S., Qadir, M. G., De La Fuente, M. I., Ivan, M. E., & Komotar, R. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2477-x · Cited by 212
Temozolomide Nanoparticles for Targeted Glioblastoma Therapy
Fang, C., Wang, K., Stephen, Z. R., Mu, Q., Kievit, F. M., Chiu, D. T., Press, O. W., & Zhang, M. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am5092165 · Cited by 204
Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers
Prosniak, M., Harshyne, L. A., Andrews, D. W., Kenyon, L. C., Bedelbaeva, K., Apanasovich, T. V., Heber-Katz, E., Curtis, M. T., Cotzia, P., & Hooper, D. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1940 · Cited by 203
Zou, Y., Liu, Y., Yang, Z., Zhang, D., Lu, Y., Zheng, M., Xue, X., Geng, J., Chung, R., & Shi, B. (2018) · Advanced Materials · doi:10.1002/adma.201803717 · Cited by 203
Schnell, O., Krebs, B., Carlsen, J., Miederer, I., Goetz, C., Goldbrunner, R. H., Wester, H.-J., Haubner, R., Pöpperl, G., Holtmannspötter, M., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-024 · Cited by 199
Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P., & Benoît, J.-P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0289 · Cited by 198
Zhang, J., Sarkar, S., Cua, R., Zhou, Y., Hader, W., & Yong, V. W. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr289 · Cited by 196
Morton, S. W., Lee, M. J., Deng, Z. J., Dreaden, E. C., Siouve, E., Shopsowitz, K. E., Shah, N. J., Yaffe, M. B., & Hammond, P. T. (2014) · Science Signaling · doi:10.1126/scisignal.2005261 · Cited by 190
Candelario-Jalil, E., Taheri, S., Yang, Y., Sood, R., Grossetete, M., Estrada, E. Y., Fiebich, B. L., & Rosenberg, G. A. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127035 · Cited by 189
Koukourakis, M. I., Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S., & Karkavitsas, N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1459 · Cited by 186
Cheng, D., Cao, N., Chen, J., Yu, X., & Shuai, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.057 · Cited by 184
Grauer, O., Jaber, M., Hess, K., Weckesser, M., Schwindt, W., Maring, S., Wölfer, J., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03005-x · Cited by 181
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02772 · Cited by 181
Convection-enhanced delivery for the treatment of glioblastoma
Vogelbaum, M. A., & Aghi, M. K. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou354 · Cited by 167
Guo, W., Sun, X., Jacobson, O., Yan, X., Min, K., Srivatsan, A., Niu, G., Kiesewetter, D. O., Chang, J., & Chen, X. (2015) · ACS Nano · doi:10.1021/nn505660r · Cited by 166
Maeda, H. (2013) · Cancer Science · doi:10.1111/cas.12152 · Cited by 163
Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy
Ozdemir-Kaynak, E., Qutub, A. A., & Yeşil-Çeliktaş, Ö. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00170 · Cited by 161
Kim, S. S., Rait, A. S., Kim, E. H., Pirollo, K. F., Nishida, M., Farkas, N., Dagata, J. A., & Chang, E. H. (2014) · ACS Nano · doi:10.1021/nn5014484 · Cited by 158
Li, D., Zhang, J., Chi, C., Xiao, X., Wang, J., Lang, L., Ali, I., Niu, G., Zhang, L., Tian, J., et al. (2018) · Theranostics · doi:10.7150/thno.25599 · Cited by 157
Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
Quantum dots hold promise for early cancer imaging and detection
Pericleous, P., Gazouli, M., Lyberopoulou, A., Rizos, S., Nikiteas, N. I., & EFSTATHOPOULOS, E. P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27528 · Cited by 145
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy
Galldiks, N., Law, I. G., Pope, W. B., Arbizu, J., & Langen, K. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.12.020 · Cited by 141
Zhao, M., Bozzato, E., Joudiou, N., Ghiassinejad, S., Danhier, F., Gallez, B., & Véronique Préat, A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.015 · Cited by 132
Self-citationThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · Neurotherapeutics · doi:10.1007/bf03206638 · Cited by 131
Interleukin-13 receptor–targeted nanovesicles are a potential therapy for glioblastoma multiforme
Madhankumar, A. B., Slagle‐Webb, B., Mintz, A., Sheehan, J. M., & Connor, J. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0480 · Cited by 130
Hao, Y., Zhang, B., Zheng, C., Ji, R., Ren, X., Guo, F., Sun, S., Shi, J., Zhang, H., Zhang, Z., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.016 · Cited by 126
Han, L., Kong, D. K., Zheng, M.-Q., Murikinati, S., Ma, C., Yuan, P., Li, L., Tian, D., Cai, Q., Ye, C., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07573 · Cited by 122
Shah, N., Chaudhari, K., Dantuluri, P., Murthy, R. S. R., & Das, S. (2009) · Journal of drug targeting · doi:10.1080/10611860903046628 · Cited by 114
Haining, Z., Kawai, N., Miyake, K., Okada, M., Okubo, S., Zhang, X., Fei, Z., & Tamiya, T. (2012) · BMC Clinical Pathology · doi:10.1186/1472-6890-12-4 · Cited by 108
Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil
Soni, V., Kohli, D. V., & Jain, S. K. (2005) · Journal of drug targeting · doi:10.1080/10611860500107401 · Cited by 103
Alizadeh, D., Zhang, L., Hwang, J., Schluep, T., & Badie, B. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.10.001 · Cited by 103
Shen, Y., Pi, Z., Yan, F., Yeh, C., Zeng, X., Diao, X., Hu, Y., Chen, S., Chen, X., & Zheng, H. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s136401 · Cited by 101
Theek, B., Gremse, F., Kunjachan, S., Fokong, S., Pola, R., Pechar, M., Deckers, R., Storm, G., Ehling, J., Kiessling, F. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.007 · Cited by 100
The Structure and Functions of P-Glycoprotein
Li, Y., Yuan, H., Yang, K., Xu, W., Tang, W., & Li, X. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790514507 · Cited by 100
Ganipineni, L. P., Učakar, B., Joudiou, N., Bianco, J. I., Danhier, P., Zhao, M., Bastiancich, C., Gallez, B., Danhier, F., & Véronique Préat, A. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165184 · Cited by 100
Self-citationXu, H., Yang, J., ZhuGe, D., Lin, M., Zhu, Q., Jin, B., Tong, M., Shen, B., Xiao, J., & Zhao, Y. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701130 · Cited by 98
Zhao, L., Li, Y., Zhu, J., Sun, N., Song, N., Xing, Y. T., Huang, H., & Zhao, J. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0462-6 · Cited by 96
Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database
Trifiletti, D. M., Alonso, C. E., Grover, S., Fadul, C. E., Sheehan, J. P., & Showalter, T. N. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.04.035 · Cited by 95
Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches
Huang, W., Chen, W., & Zhang, X. (2016) · Oncology Letters · doi:10.3892/ol.2016.4952 · Cited by 94
Reichman, H. R., Farrell, C. L., & Maestro, R. F. D. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.2.0233 · Cited by 92
Stylli, S. S., Luwor, R. B., Ware, T. M. B., Tan, F. H., & Kaye, A. H. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.013 · Cited by 86
Nanoparticle-based diagnostic and therapeutic systems for brain tumors
Wu, X., Yang, H. N., Yang, W., Chen, X., Gao, J., Gong, X., Wang, H., Duan, Y., Wei, D., & Chang, J. K. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00860h · Cited by 83
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2020) · doi:10.1201/9780429399039-10 · Cited by 81
Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis
D, J.-M. L. M., Clavreul, A., Aubry, M., Com, E., de Tayrac, M., Eliat, P., Henry, C., Rousseau, A., Mosser, J., & Meneï, P. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1695-8 · Cited by 79
Bergamino, M., Bonzano, L., Levrero, F., Mancardi, G., & Roccatagliata, L. (2014) · Physica Medica · doi:10.1016/j.ejmp.2014.04.005 · Cited by 74
Iron oxide-carbon core-shell nanoparticles for dual-modal imaging-guided photothermal therapy
Wang, H., Mu, Q., Revia, R. A., Wang, K., Tian, B., Lin, G., Lee, W., Hong, Y., & Zhang, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.022 · Cited by 74
Zhou, Z., Kennell, C., Jafari, M., Lee, J., Ruiz-Torres, S. J., Waltz, S. E., & Lee, J.-H. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.085 · Cited by 69
Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment
Bastiancich, C., Bozzato, E., Luyten, U., Danhier, F., Bastiat, G., & Véronique Préat, A. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.01.042 · Cited by 67
Liu, C., Chen, J., Zhu, Y. J., Gong, X., Zheng, R., Chen, N., Chen, D., Yan, H., Zhang, P., Zheng, H., et al. (2018) · Nano-Micro Letters · doi:10.1007/s40820-018-0202-8 · Cited by 65
Nanomedicine for Spontaneous Brain Tumors: A Companion Clinical Trial
Arami, H., Patel, C. B., Madsen, S. J., Dickinson, P. J., Davis, R. M., Zeng, Y., Sturges, B. K., Woolard, K., Habte, F. G., Akin, D., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b04406 · Cited by 64
Simeonova, I., & Huillard, E. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1675-3 · Cited by 61
Chen, X., Tai, L., Gao, J., Qian, J., Zhang, M., Li, B., Xie, C., Lu, L., Lu, W., & Lu, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.061 · Cited by 60
Self-assembled 20-nm 64Cu-micelles enhance accumulation in rat glioblastoma
Seo, J. W., Ang, J., Mahakian, L. M., Tam, S. M., Fite, B. Z., Ingham, E. S., Beyer, J., Forsayeth, J., Bankiewicz, K. S., Xu, T., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.057 · Cited by 60
Anton, N., Anton, H., Porcher, E., Benoît, J., & Saulnier, P. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.039 · Cited by 59
Dynamic Susceptibility Contrast MR Imaging in Glioma
Boxerman, J. L., Shiroishi, M. S., Ellingson, B. M., & Pope, W. B. (2016) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2016.06.005 · Cited by 55
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Asklund, T., Kvarnbrink, S., Holmlund, C., Wibom, C., Bergenheim, T. A., Henriksson, R., & Hedman, H. (2012) · PubMed · Cited by 53
Liu, Y., Liu, J., Zhang, J., Li, X., Lin, F., Zhou, N., Yang, B., & Lu, L. (2018) · ACS Omega · doi:10.1021/acsomega.8b01169 · Cited by 53
Verduin, M., Compter, I., Steijvers, D., Postma, A. A., Eekers, D. B. P., Anten, M. H. M. E., Ackermans, L. P. C. M., ter Laan, M., Leijenaar, R. T. H., van de Weijer, T., et al. (2018) · Disease Markers · doi:10.1155/2018/2908609 · Cited by 50
The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II
Smits, A., & Baumert, B. G. (2011) · International Journal of Molecular Imaging · doi:10.1155/2011/372509 · Cited by 44
Paclitaxel Tumor-Priming Enhances siRNA Delivery and Transfection in 3-Dimensional Tumor Cultures
Wong, H. L., Shen, Z., Lu, Z., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1004383 · Cited by 42
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Quinn, J. A., Jiang, X. “., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-007 · Cited by 42
Quantum Dots as Multifunctional Materials for Tumor Imaging and Therapy
Liu, L., Miao, Q., & Liang, G. (2013) · Materials · doi:10.3390/ma6020483 · Cited by 40
Multiple functionalized carbon quantum dots for targeting glioma and tissue imaging
Gao, L., Zhao, X., Wang, J., Wang, Y., Yu, L., Peng, H., & Zhu, J. (2017) · Optical Materials · doi:10.1016/j.optmat.2017.11.044 · Cited by 40
Moore, T. L., Hauser, D., Gruber, T., Rothen‐Rutishauser, B., Lattuada, M., Petri‐Fink, A., & Lyck, R. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03479 · Cited by 37
Roode, L. E., Brighton, H. E., Bo, T., Perry, J. L., Parrott, M. C., Kersey, F. R., Luft, J. C., Bear, J. E., DeSimone, J. M., & Davis, I. J. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.382 · Cited by 34
Shi, Z., Qian, X., Liu, C., Han, L., Zhang, K., Chen, L., Zhang, J., Pu, P., Yuan, X., Kang, C., et al. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12041 · Cited by 30
Young, J. S., Dayani, F., Morshed, R. A., Okada, H., & Aghi, M. K. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2018.12.222 · Cited by 28
Cited by
Shi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
Liu, S., Liu, J., Li, H., Mao, K., Wang, H., Meng, X., Wang, J., Wu, C., Chen, H., Wang, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121645 · Cited by 122
Metadata
- Authors
- Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 3
- Pages
- 1355-1372
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2997516063
- Cited by
- 373
- References
- 142
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.